CBP 501

Drug Profile

CBP 501

Alternative Names: CBP-501; Cdc25C phosphatase (211-221)

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CanBas
  • Class Antineoplastics; Peptides
  • Mechanism of Action 14-3-3 protein inhibitors; Calmodulin modulators; Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I Solid tumours
  • Discontinued Ovarian cancer

Most Recent Events

  • 04 Jul 2017 CBP 501 is still in phase II development for Mesothelioma and Non-small-cell lung cancer (CanBas pipeline, July 2017)
  • 03 Jul 2017 Phase II trial of CBF 501 fails to meet its primary endpoint of progression free survival in patients with non-small-cell lung cancer
  • 09 Apr 2017 CanBas plans a phase Ib trial in Solid tumours (Late-stage disease, Second-line or greater therapy, Combination therapy) (NCT03113188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top